QUOTE AND NEWS
FiercePharma  May 28  Comment 
Cancer drug spending is up. Cancer drug prices are way up. And as a new Express Scripts report shows, spending on each cancer patient is mounting; it's among the reasons why a growing number of individual patients account for $100,000-plus in...
FierceBiotech  May 27  Comment 
Two of the cancer drugs Novartis traded for from GSK--Tafinlar and Mekinist--will post combo survival data at ASCO.
The Economic Times  May 27  Comment 
Pharmaceuticals firm Novartis India today reported over two-fold increase in standalone net at Rs 51.94 crore for the fourth quarter ended March 31, 2015.
The Hindu Business Line  May 27  Comment 
newratings.com  May 27  Comment 
Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA Novartis International AG / Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA . Processed and transmitted by...
Market Intelligence Center  May 26  Comment 
Novartis AG (NVS) is a good candidate for a covered call at the $100.00 level. The Oct. '15 call at that price should fetch a credit of about $6.60, which means the entire position has a net debit of about $97.25. This trade has 4.48% downside...
FierceBiotech  May 22  Comment 
Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.
Forbes  May 22  Comment 
Entresto. That's the brand name Novartis has chosen for LCZ696, its new heart failure drug that is expected to be a blockbuster. The name won't be final until official confirmation, which comes with FDA approval. But Novartis will...
newratings.com  May 21  Comment 
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors Novartis International AG / Novartis drug Afinitor® extended progression-free survival in Phase III trial...
Benzinga  May 20  Comment 
Novartis announced today positive results from two pivotal Phase III clinical trial programs for QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide) in patients with moderate-to-severe chronic obstructive pulmonary...
newratings.com  May 20  Comment 
Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 Novartis International AG / Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 . Processed and transmitted by NASDAQ OMX...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki